Constipation Risk Across Tirzepatide Dosing and Patient Factors Constipation incidence correlates with dose escalation, baseline GI function, hydration status, physical activity levels, and individual genetic variations in GLP-1 and GIP receptor sensitivity
Overview of Glucagon-like Peptide-1 (glp-1) Receptor Agonists As research continues, the potential applications of Semaglutide may extend beyond weight management, sparking interest in its effects on metabolic disorders, cardiovascular health, and even type 2 diabetes
The company is interested in making money, and not having any checks and balances to ensure that it is safe. OpenAI has something of a history of releasing products before the industry thinks theyre ready
Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
A literature overview
You dont need to become an athlete